RGNX analyst estimates
REGENXBIO (RGNX) analyst ratings, the average price target and its range, and every firm's latest call.
RGNX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 5, 2026 | Mizuho Securities | Regenxbio initiated with an Outperform at Mizuho | $22.00 |
| Aug 25, 2026 | Robert W. Baird | Regenxbio price target lowered to $29 from $32 at Baird | $29.00 |
| Aug 25, 2026 | H.C. Wainwright | Regenxbio price target lowered to $21 from $23 at H.C. Wainwright | $21.00 |
| Aug 10, 2026 | H.C. Wainwright | Regenxbio price target lowered to $23 from $26 at H.C. Wainwright | $23.00 |
| Aug 7, 2026 | Morgan Stanley | Regenxbio price target raised to $18 from $16 at Morgan Stanley | $18.00 |
| Jul 1, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX) | $26.00 |
| Jun 22, 2026 | Robert W. Baird | Regenxbio Inc. (RGNX) PT Raised to $32 at Baird | $32.00 |
| Jun 22, 2026 | Leerink Partners | Regenxbio Inc. (RGNX) PT Raised to $18 at Leerink | $18.00 |
| May 15, 2026 | Barclays | Regenxbio price target lowered to $12 from $37 at Barclays | $12.00 |
| May 15, 2026 | Morgan Stanley | Regenxbio price target lowered to $16 from $17 at Morgan Stanley | $16.00 |
| Mar 9, 2026 | H.C. Wainwright | Regenxbio price target lowered to $30 from $32 at H.C. Wainwright | $30.00 |
| Mar 5, 2026 | Morgan Stanley | Regenxbio Inc. (RGNX) PT Lowered to $17 at Morgan Stanley | $17.00 |
| Feb 10, 2026 | UBS | Regenxbio price target lowered to $18 from $25 at Morgan Stanley | $18.00 |
| Feb 10, 2026 | Robert W. Baird | Regenxbio price target lowered to $27 from $39 at Baird | $27.00 |
| Feb 10, 2026 | H.C. Wainwright | Regenxbio price target lowered to $32 from $34 at H.C. Wainwright | $32.00 |
- 11 firms rate RGNX: 9 buy, 2 hold, 0 sell.
- The average price target is $20.00 from 6 analysts, from $12.00 to $29.00.
Updated 2026-11-05 12:48 UTC